Synopsis: Jenburkt Pharmaceuticals Limited reported Q4FY26 revenue of Rs. 44.63 crore and net profit of Rs. 10.85 crore. While revenue declined marginally on a year-on-year basis, profit increased around 27 percent due to improved operating efficiency, favorable inventory adjustments and lower cost pressures.
Jenburkt has a total market capitalization of Rs. 507.53 crore, according to data on the BSE. Jenburkt shares were trading at Rs. 1,158 apiece on the Bombay Stock Exchange, up by 7.77 percent; the stock has gained around 10.92 percent over the last five sessions, while it has surged about 14.65 percent in the 30 days. Over a six-month period, the stock has given a negative return of 4.83 percent, whereas on a year-on-year basis it has an uptrend of nearly 17.46 percent, reflecting good overall performance. The stock’s 52-week high was Rs. 1410 and 52-week low was Rs.944.
Jenburkt Pharmaceuticals Limited reported a mixed yet operationally strong set of results for the quarter ended March 31, 2026. The company posted revenue from operations of Rs. 44.63 crore in Q4FY26 compared to Rs. 41.05 crore in Q4FY25, registering a growth of around 8.7 percent on a year-on-year basis. Total income stood at Rs. 48.98 crore compared to Rs. 42.93 crore in the corresponding quarter last year, reflecting an increase of approximately 14.1 percent, supported by higher other income and improved business activity.
On the profitability front, the company reported a net profit of Rs. 10.85 crore in Q4FY26 compared to Rs. 8.54 crore in Q4FY25, reflecting a strong growth of around 27 percent on a year-on-year basis. The improvement in profitability was significantly higher than revenue growth, indicating strong margin expansion and improved operational efficiency during the quarter.
A key reason behind the profit growth was the sharp improvement in inventory-related adjustments. The company reported a negative inventory change of Rs. 2.23 crore in Q4FY26 compared to a positive Rs. 0.38 crore in Q4FY25. Despite this negative adjustment, profitability improved due to better control over other operating costs and stronger contribution from higher-margin products.
Employee benefit expenses declined significantly to Rs. 9.52 crore from Rs. 11.43 crore in the same quarter last year, reflecting a reduction of around 16.8 percent, which directly supported margin expansion. Additionally, finance costs remained low at Rs. 0.13 crore, indicating limited debt burden and healthy balance sheet strength.
At the operating level, profit before tax stood at Rs. 13.71 crore in Q4FY26 compared to Rs. 11.84 crore in Q4FY25, registering a growth of around 15.8 percent. The company also accounted for an impact of revised labour codes amounting to Rs. 3.95 crore during the quarter, which impacted reported profitability. Excluding this one-time adjustment, operational profitability would have been even stronger.
Margins improved despite rising other expenses, which increased to Rs. 12.20 crore from Rs. 10.85 crore in the previous year quarter. Total expenses stood at Rs. 31.32 crore compared to Rs. 31.09 crore in Q4FY25, reflecting only a marginal increase of around 0.7 percent, while total income grew over 14 percent. This operating leverage significantly boosted earnings.
For the full financial year FY26, the company reported revenue from operations of Rs. 168.74 crore compared to Rs. 151.69 crore in FY25, reflecting a growth of around 11.2 percent. Net profit for the year stood at Rs. 34.74 crore compared to Rs. 32.06 crore in the previous year, indicating a growth of approximately 8.4 percent.
However, full-year margins remained somewhat impacted due to higher purchase of stock-in-trade and rising operating expenses during the year. Purchase of stock-in-trade increased sharply to Rs. 28.17 crore from Rs. 21.26 crore, indicating increased procurement costs and higher product distribution activity. Earnings per share (EPS) for FY26 stood at Rs. 78.71 compared to Rs. 72.65 in FY25, reflecting improved shareholder returns and stable earnings growth.
The Board of Directors has also recommended a dividend of Rs. 220.70 per equity share, representing 207 percent on the face value of Rs. 10 each, for the financial year 2025–26. The dividend will be payable on 44,13,300 equity shares of the company, reflecting management’s confidence in the company’s cash flow position and long-term financial stability. The strong dividend payout indicates a shareholder-friendly capital allocation approach and demonstrates the company’s ability to maintain healthy returns despite ongoing operational and regulatory cost pressures.
Overall, the Q4FY26 and FY26 results indicate that Jenburkt Pharmaceuticals is maintaining steady growth momentum with improving operational efficiency. Going forward, the company’s performance will depend on sustaining revenue growth, managing input costs and maintaining margins amid evolving regulatory and industry dynamics.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
